{
IDN

Country

}
global uveitis treatment market poised for significant growth by 2032
The Global Uveitis Treatment market is projected to grow from USD 725 million in 2024 to USD 1.28 billion by 2032, with a CAGR of 8.5%. The study covers various treatment types, including corticosteroids and biologic agents, and offers customization options for regional and application-specific analysis. Key players include Novartis, Pfizer, and AbbVie, with North America leading the market and Asia-Pacific identified as the fastest-growing region.
openPR.com
Pfizer Inc. Bayer AG Novartis AG Regeneron Pharmaceuticals, Inc. Merck & Co., Inc. CIPLA LTD Lupin Limited Hoffmann-La Roche AG Bausch Health Companies Inc. BIOGEN ABBVIE Alimera Sciences Inc. SAU ISR FRA RUS DEU TWN ARG ARE AUT TUR SGP NZL CHL USA BRA CAN ITA JPN IDN GBR ESP IND MYS COL AUS THA EGY VNM KOR PHL CHN ZAF MEX Nidhi Bhavsar Show more
Healthcare, Market Report
20:41 19.12.2024
global fermented beverages market analysis trends and growth prospects through 2032
The Global Fermented Beverages market, valued at 860 billion USD in 2024, is projected to reach 1.3 trillion USD by 2032, growing at a CAGR of 6.4%. The market analysis covers major regions including North America, Europe, and Asia-Pacific, with customization options available for specific countries and applications. Key players include Apple, Microsoft, and Nestlé, with insights into market dynamics, competitive landscape, and growth drivers such as lifestyle changes and technological advancements in fermentation.
openPR.com
United States Dollar Euro Microsoft Corporation Apple Inc. Toyota Motor Corporation Procter & Gamble Co Amazon.com, Inc. Tencent Holdings Limited Johnson & Johnson Samsung Electronics Co., Ltd. JPMorgan Chase & Co. Nestlé S.A. Alibaba Group Holding Limited Alphabet Inc. SAU ISR FRA RUS DEU TWN ARG ARE AUT TUR SGP NZL CHL USA BRA CAN ITA JPN IDN GBR ESP IND MYS COL AUS THA EGY VNM KOR PHL CHN ZAF MEX Nidhi Bhavsar Show more
Regulatory & Legal, Market Report
15:21 19.12.2024
solaxy raises nearly three million dollars in token presale launch
Solaxy, a new Layer-2 scaling solution for the Solana blockchain, has raised nearly $3 million in its token presale within its first week. The SOLX tokens are currently priced at $0.00157, with staking rewards available over three years. Designed to alleviate network congestion, Solaxy utilizes a rollup architecture to enhance transaction throughput and facilitate interoperability between Solana and Ethereum.
Crypto News Flash
IDN
Technology & Innovation, Press Release
13:37 19.12.2024
solaxy raises nearly three million dollars in token presale launch
Solaxy (SOLX), a new Layer-2 scaling solution for the Solana blockchain, has raised nearly $3 million in its token presale within its first week. The presale, which allows payments in ETH, USDT, and credit/debit cards, offers staking rewards over three years and has been audited by Coinsult with no vulnerabilities found. Solaxy aims to alleviate network congestion by processing transactions off the main chain and enhancing interoperability between Solana and Ethereum, potentially paving the way for cross-chain applications.
markets.businessinsider.com
IDN
Technology & Innovation, Press Release
13:36 19.12.2024
global bisoprolol fumarate market poised for significant growth through 2032
The Global Bisoprolol Fumarate market is projected to grow from USD 1.3 billion in 2023 to USD 2.0 billion by 2032, with a CAGR of 7%. This medication, primarily used for hypertension and heart-related conditions, is expected to see increased demand driven by regulatory changes and market dynamics across various regions, particularly in Europe and Asia-Pacific. Key players include Merck, Pfizer, and Novartis, with a focus on understanding market trends and competitive strategies.
openPR.com
United States Dollar Merck & Co., Inc. Amgen Inc. Alkem Laboratories Limited Mylan Pharmaceuticals Inc. Aurobindo Pharma Limited Teva Pharmaceutical Industries Ltd Dr. Reddy's Laboratories Limited Glenmark Pharmaceuticals Limited CIPLA LTD Sandoz Group AG Pfizer Inc. Bayer AG Hikma Pharmaceuticals PLC AstraZeneca PLC Novartis AG Torrent Pharmaceuticals Limited Sanofi IND ROU BEL HUN DNK POL IDN SGP ARE BRA ZAF FRA THA MEX CZE GBR CHL AUT SAU SWE NOR NLD USA ARG MYS SVK CAN NZL LKA JPN DEU RUS KOR CHN VNM Nidhi Bhavsar Show more
Regulatory & Legal, Market Report
13:09 16.12.2024
asia stocks decline as investors await fed rate decision and china data
Most Asian stocks declined ahead of the U.S. Federal Reserve's interest rate decision, with Chinese shares falling due to disappointing retail sales data, raising concerns about the economy's recovery. Japan's market remained stable as the Bank of Japan is expected to maintain current rates, while South Korea's index showed little change following the president's impeachment. Overall, investor sentiment was cautious globally as markets awaited clarity from the Fed amidst persistent inflation concerns.
investing.com
Chinese Yuan Australian Dollar United States Dollar Japanese Yen South Korean Won Bank of Japan MYS IND IDN HKG AUS KOR CHN JPN Yoon Suk Yeol Show more
Finance & Economy, Market Report
04:20 16.12.2024
global bromhexine tablet market projected to reach 1131 million by 2032
The Global Bromhexine Tablet market is projected to grow from USD 875.5 million in 2023 to USD 1,131.7 million by 2032, with a CAGR of 3.7% from 2024 to 2032. This growth is driven by the rising prevalence of respiratory disorders and increasing demand for expectorants. Key players include Sanofi, Teva, and Boehringer Ingelheim, with market segmentation covering applications, types, and distribution channels across various regions.
openPR.com
GSK plc Aspen Pharmacare Holdings Ltd Boehringer Ingelheim KG Novartis AG Sanofi MYS IND PHL IDN HKG SGP TWN JPN THA AUS KOR CHN VNM Nidhi Bhavsar Show more
Healthcare, Market Report
08:02 14.12.2024
global growth trends in the crispr and cas gene market to 2033
The global CRISPR and Cas gene market reached approximately $3.3 billion in 2023, growing at a CAGR of 20.38% since 2018. It is projected to expand to $8.8 billion by 2028 and $24.6 billion by 2033, driven by advancements in cancer therapeutics and gene therapy research. North America leads the market, accounting for 45.3% of the total value in 2023.
GlobeNewswire News Room
United States Dollar Bayer AG Bio-Rad Laboratories, Inc. Pluristem Therapeutics Inc. Genscript Biotech Corporation AstraZeneca PLC Qiagen N.V. Hologic, Inc. Cellectis S.A. Takara Bio Inc. Vertex Pharmaceuticals Inc Thermo Fisher Scientific Inc. Sigma-Aldrich Co. LLC Regeneron Pharmaceuticals Inc Editas Medicine Inc IND GBR ESP CAN AUS ITA IDN JPN BRA DEU FRA RUS KOR CHN USA Show more
Technology & Innovation, Market Report
15:27 13.12.2024
Heidelberg Materials Reports Diverse Global Sales in Cement and Building Materials
Heidelberg Materials AG, a leader in cement and building materials, reports its sales distribution as follows: cements (45.5%), ready-mix concrete and asphalt (27.5%), aggregates (18%), and other products (9%). Geographically, sales are concentrated in the United States (20.4%), Germany (9%), and the United Kingdom (8.9%), among other regions.
zonebourse.com
United States Dollar Heidelberg Materials AG USA DEU ITA IDN CAN FRA AUS GBR Show more
TradFi, Market Report
07:54 13.12.2024
emerging markets drive significant growth in global cryptocurrency adoption
[SEC]
Crypto News Flash
Quidax Token USD NGA ZAF IDN IND Emomotimi Agama Show more
Finance & Economy, Market Report
13:00 12.12.2024
Trending
Subcategory:
Cryptocurrency Markets Stock Market Updates Cryptocurrency Trends Market Sentiment Analysis Banking Regulations Central Bank Actions Corporate Responsibility & ESG Decentralized Finance (DeFi) Innovations Tokenomics and Crypto Economics Cryptocurrency & Blockchain Regulations Mergers & Acquisitions Cryptocurrency Developments Blockchain Technology Adoption Anti-Money Laundering (AML) Regulations Market Analysis and Predictions Cryptocurrency Regulations Emerging Startups SEC & Financial Compliance Inflation Rates & CPI Data Banking & Investment Regulations
Countries:
USA CHE GBR DEU ARE HKG AUS JPN IND CHN CAN SGP DNK AUT LIE KOR NGA FIN COL VGB
Companies:
Credit Suisse Real Estate Fund Siat Coinbase Global, Inc. BlackRock, Inc. Solana USD Ripples USD Ethereum USD Apple Inc. Tesla, Inc. Fidelity Contrafund Cardano USD NVIDIA Corporation Grayscale Litecoin Trust Chainlink USD Tether USDt CNY Google Inc. Amazon.com, Inc. MicroStrategy Inc Franklin Templeton - Franklin M End Federal Reserve USD MicroStrategy Incorporated
Currencies:
United States Dollar Euro Swiss Franc Japanese Yen Australian Dollar Indian Rupee Canadian Dollar Mozambican Metical British Pound Sterling Norwegian Krone Mongolian Tögrög Colombian Peso Singapore Dollar
People:
Donald Trump Ali Martinez Elon Musk Karin Keller-Sutter Jerome Powell Ueli Maurer Michael J. Saylor Gary Gensler Thomas Jordan Colm Kelleher Alan Santana Paul Atkins Joe Rogan Martin Schlegel Isabelle Chassot Mario Nawfal Paolo Ardoino Sergio Ermotti Dana White Joe Biden

MachinaCore is a highly modular and scalable system that allows users to build custom widgets and tools tailored to their specific financial data needs, while seamlessly integrating with other MachinaLabs products, like Machinary, MachinaAI Modules and MachinaTrader.

Links

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.